BioLineRx (BLRX) Net Income towards Common Stockholders Growth (5y) (2018 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.07% |
| Sep 30, 2025 | 18.74% |
| Jun 30, 2025 | 21.44% |
| Mar 31, 2025 | 23.22% |
| Dec 31, 2024 | 15.40% |
| Sep 30, 2024 | 10.51% |
| Jun 30, 2024 | 11.68% |
| Mar 31, 2024 | 7.52% |
| Dec 31, 2023 | -15.56% |
| Sep 30, 2023 | -13.14% |
| Jun 30, 2023 | -8.43% |
| Mar 31, 2023 | -7.45% |
| Dec 31, 2022 | 2.23% |
| Sep 30, 2022 | 0.57% |
| Jun 30, 2022 | -7.89% |
| Mar 31, 2022 | -3.79% |
| Dec 31, 2021 | -7.38% |
| Sep 30, 2021 | -6.49% |
| Jun 30, 2021 | -10.23% |
| Mar 31, 2021 | -6.76% |
| Dec 31, 2020 | -5.86% |
| Sep 30, 2020 | -4.68% |
| Jun 30, 2020 | -5.34% |
| Mar 31, 2020 | -8.21% |
| Dec 31, 2019 | -17.48% |
| Sep 30, 2019 | -26.69% |
| Jun 30, 2019 | -11.26% |
| Mar 31, 2019 | -6.22% |
| Dec 31, 2018 | -26.91% |
| Sep 30, 2018 | -18.57% |
| Jun 30, 2018 | -7.44% |
| Mar 31, 2018 | -1.61% |